Background:Cancers in teenage and young adults (TYAs), though an increasing cause of mortality in our country, have been scarcely studied. The lack of studies of TYAs can significantly affect the outcomes of the youth in the prime of their lives.Aims:The aim of this study was to study the type of cancers in the TYA at a rural cancer center in central India.Design and Methods:A prospective study in the department of medical oncology, from the period of January 2013 till March 2016, was done. Data regarding socioepidemiological factors were collected for new cancer patients between the age group of 15–30 years in semi-structured questionnaire and from the hospital records. Cancers were classified according to the Birch classification. The cases were analyzed according to the epidemiological profile, classification of cancer, and age-wise distribution using descriptive analysis.Results:In this study, out of 5221 cancer patients, TYAs accounted for 327 (6.26%) with 189 males and 138 females (M: F– 1.37:1). The maximum cases were seen in 25–30 years’ age group. Carcinoma was the most common malignancy (54.74%) with an increase from 19.56% in the 15–19 years’ age group to 64.82% in the 25–30-year-old patients.Conclusion:The present study gives a glimpse of the TYA cancers in the central India. More than half of the young cancer patients suffer from carcinomas with about half of these being head and neck cancers.

Breast cancer is a public health challenge globally as well as in India. Improving outcome and cure requires appropriate biomarker testing to assign risk and plan treatment. Because it is documented that significant ethnic and geographical variations in biological and genetic features exist worldwide, such biomarkers need to be validated and approved by authorities in the region where these are intended to be used. The use of western guidelines, appropriate for the Caucasian population, can lead to inappropriate overtreatment or undertreatment in Asia and India. A virtual meeting of domain experts discussed the published literature, real-world practical experience, and results of opinion poll involving 185 oncologists treating breast cancer across 58 cities of India. They arrived at a practical consensus recommendation statement to guide community oncologists in the management of hormone positive (HR-positive) Her2-negative early breast cancer (EBC). India has a majority (about 50%) of breast cancer patients who are diagnosed in the premenopausal stage (less than 50 years of age). The only currently available predictive test for HR-positive Her2-negative EBC that has been validated in Indian patients is CanAssist Breast. If this test gives a score indicative of low risk (< 15.5), adjuvant chemotherapy will not increase the chance of metastasis-free survival and should not be given. This is applicable even during the ongoing COVID-19 pandemic.

20015 Background: Acute Lymphatic Leukemia in children is a curable disease in the range of 80–90 % in developed Countries by aggressive protocol like BFM, St. Judes’. In developing Countries like ours, patients can’t tolerate those aggressive protocol because of Socio- economic and nutritional factors. The less aggressive Protocol like INCTR (International Network for Cancer Treatment & Research) are suitable in developing Countries like ours. The aim of our study was to see outcome of childhood ALL patient with INCTR protocol and tolerability of the protocol in Indian-asian population. Methods: We treated 480 Children (age range 1–25 years, median age of 11 yrs) with INCTR Protocol at Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, India, a tertiary cancer centre from Eastern India during period from April ’99 to Dec ’06. There was female preponderance in the study. Fever 283 (58.9%), lymphadenopathy 211 (43.9%) and haepatosplenomegaly 153 (31.8%) were the major clinical presentation. Forty-three (8.9%) patients were present with hyper Leukocytosis. C-ALL phenotype were the largest group though the incidence of the T-ALL were quite high (27.9%). Results: Remission induction were seen in 446 (92.9%) of the patient. In a follow-up period of 88 months (with an average of 54 months) the disease-free survival ( DFS) was 66.8% (321 patients) with an overall survival of 73.9% (355 patients). The isolated bone marrow relapse was seen in majority of the cases 40 (8.33%) and the major relapse was in maintenance and first 6 months of completion of therapy. The major cause of morbidity was infection 316 (65.8%) followed metabolic complications 81 (16.8%), hemorrhage 52 (10.8%), neurologic 10 (2.08%), hepatitis 6 (1.25%) and pancreatitis 5 (1.04%). The major cause of the mortality was infection 75%(360 patients) followed progressive disease 7.91% (38 patients) and Hemorrhage 5.83%( 28 patients). Conclusions: The data of acute lymphatic leukemia from a developing country is encouraging. The protocol was well tolerated by India- asian population. No significant financial relationships to disclose.

Introduction: Hepatocellular Carcinoma (HCC) is a common malignancy of gastrointestinal tract presenting in clinical practice. The common etiologies are hepatitis B virus (HBV), hepatitis C virus (HCV) and alcohol consumption. Treatment of HCC is multimodality based on Barcelona Clinic Liver Cancer (BCLC) staging system. The aim of the article is to study the demographic, clinico-radiological profile and treatment patterns of HCC patients. Methods: This is a retrospective cross sectional study of patients diagnosed as HCC at Shree Birendra Hospital, Chhauni, Kathmandu, Nepal from April 2017 to March 2020. The study was approved by Institutional Review Committee. Data were collected for demography, clinical feature, histology, HBsAg status, serum AFP values, radiological findings and treatment details from hospital record. Data were analysed using Excel 2010 and SPSS v 21. Results: Total of 36 patients diagnosed with HCC were included for analysis. There was a male predominance (72.22%) and the mean age was 66.75 ± 12.02 years. Pain abdomen and jaundice were present in 63.89% and 38.89% respectively at presentation and features of chronic liver disease (CLD) were evident in 83.33%. HBsAg was present in 44.44% of HCC. Location of tumour was primarily in right lobe (80.56%) and size of lesion varied greatly. Tissue diagnosis was obtained in 52.78% patients. Chemotherapy option was limited to Sorafenib. Conclusions: HCC is more prevalent in older males. The common modes of presentation were pain abdomen and jaundice. Most of the HCC had underlying CLD and were advanced. Sorafenib was the mainstay of treatment in advanced HCC.

No abstract